Cellosaurus logo
expasy logo

Cellosaurus ADK-VR2 AG143 (CVCL_E6J6)

[Text version]
Cell line name ADK-VR2 AG143
Accession CVCL_E6J6
Resource Identification Initiative To cite this cell line use: ADK-VR2 AG143 (RRID:CVCL_E6J6)
Comments Population: Southeast Asian; Filipino.
Characteristics: Grown in 3D culture in the presence of crizotinib. Has a significantly lower sensitivity to crizotinib than the parental cell line in adherent cultures and is not sensitive to lorlatinib, entrectinib and DS-6051b (PubMed=36519016).
Doubling time: 25.77 hours (Direct_author_submission).
Selected for resistance to: ChEBI; CHEBI_64310; Crizotinib (Xalkori).
Donor information: Established from a treatment-naive non-smoker patient (PubMed=36519016).
Miscellaneous: Doubling time and ethnic origin of patient from personal communication of Angelicola, Stefania.
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
Disease Lung adenocarcinoma (NCIt: C3512)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_E6J5 (ADK-VR2)
Sex of cell Male
Age at sampling 46Y
Category Cancer cell line
Publications

PubMed=36519016; DOI=10.21037/tlcr-22-163; PMCID=PMC9742620
Francesca Ruzzi, Stefania Angelicola, Lorena Landuzzi, Elena Nironi, Maria Sofia Semprini, Laura Scalambra, Annalisa Altimari, Elisa Gruppioni, Michelangelo Fiorentino, Francesca Giunchi, Manuela Ferracin ...Show all 18 authors... , Annalisa Astolfi, Valentina Indio, Andrea Ardizzoni, Francesco Gelsomino, Patrizia Nanni, Pier-Luigi Lollini, Arianna Palladini; Show fewer authors
ADK-VR2, a cell line derived from a treatment-naive patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC.
Transl. Lung Cancer Res. 11:2216-2229(2022)

Entry history
Entry creation10-Apr-2025
Last entry update10-Apr-2025
Version number1